The FDA Group's Insider Newsletter

Share this post

RA/QA News Roll: Late July 2023

insider.thefdagroup.com

RA/QA News Roll: Late July 2023

Here's what's happening at FDA and across the broader life science RA/QA space.

The FDA Group
Jul 28, 2023
∙ Paid
3
Share this post

RA/QA News Roll: Late July 2023

insider.thefdagroup.com
Share

This is our biweekly recap of news and industry happenings curated for our paid subscribers. Our goal is to bring you the headline news as well as the stories, research, and insights that might be harder to find.

If you haven’t upgraded to a paid subscription yet, you can do so here.

Here are some key items from the past couple of weeks.

FDA Guidances


  • FDA released an updated version of its guidance on the Qualification of Medical Device Development Tools. The original guidance was published in its final form in August 2017. The recent final version is a few pages shorter, and the changes are mostly minor procedural updates and clarifications.

  • FDA has issued final guidance on CDER's Program for the Recognition of Voluntary Consensus Standards Related to Pharmaceutical Quality. It outlines the agency's approach to recognizing voluntary consensus standards relevant to pharmaceutical quality.

Keep reading with a 7-day free trial

Subscribe to

The FDA Group's Insider Newsletter
to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
Previous
Next
© 2023 The FDA Group, LLC
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great writing